Struggling GSK recruits cancer drug guru Hal Barron as its new R&D chief
GlaxoSmithKline has recruited Hal Barron, one of the world’s top cancer drug investigators, to take the helm of its troubled pharma R&D group, offering a fresh sign that the pharma giant is jumping back in a big way into oncology.
Barron became something of a living legend during his long stint at Genentech during a time the big biotech carved a broad path in the oncology field. After the Roche buyout he become CMO at the pharma giant. More recently, he joined the stealthy Google startup Calico to delve into aging R&D, where he’s been largely mum about his work.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
